|Dr. Deborah Rathjen B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE||CEO, MD & Exec. Director||N/A||N/A||59|
|Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS||Legal Counsel and Company Sec.||321.7k||N/A||N/A|
|Mr. Steve Lydeamore||Chief Financial Officer||N/A||N/A||N/A|
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The companys product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials and Phase I multiple ascending dose trials for the treatment of generalized anxiety disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a novel compound to disrupt the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has collaboration agreement with Merck & Co. to develop compounds targeting cognitive impairment in conditions, such as ADHD, alzheimers disease, parkinsons disease, and schizophrenia. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Bionomics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.